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Abstract 44 
Background & Aims: The intestinal microbiota is closely associated with resident memory 45 
lymphocytes in mucosal tissue. We sought to understand how acquired cellular and humoral 46 
immunity to the microbiota differ in health versus inflammatory bowel disease (IBD).  47 
Methods: Resident memory T-cells (Trm) in colonic biopsies and local antibody responses to 48 
intraepithelial microbes were analyzed. Systemic antigen-specific immune T- and B-cell 49 
memory to a panel of commensal microbes was assessed.  50 
Results: Systemically, healthy blood showed CD4 and occasional CD8 memory T-cell 51 
responses to selected intestinal bacteria but few memory B-cell responses. In IBD, CD8 52 
memory T-cell responses decreased although B-cell responses and circulating plasmablasts 53 
increased. Possibly secondary to loss of systemic CD8 T-cell responses in IBD, dramatically 54 
reduced numbers of mucosal CD8+ Trm and γδ T-cells were observed. IgA responses to 55 
intraepithelial bacteria were increased. Colonic Trm expressed CD39 and CD73 56 
ectonucleotidases, characteristic of regulatory T-cells. Cytokines/factors required for Trm 57 
differentiation were identified, and in vitro-generated Trm expressed regulatory T-cell 58 
function via CD39. Cognate interaction between T-cells and dendritic cells induced T-bet 59 
expression in dendritic cells, a key mechanism in regulating cell-mediated mucosal 60 
responses.  61 
Conclusions: A previously unrecognized imbalance exists between cellular and humoral 62 
immunity to the microbiota in IBD, with loss of mucosal T-cell-mediated barrier immunity 63 
and uncontrolled antibody responses. Regulatory function of Trm may explain their 64 
association with intestinal health. Promoting Trm and their interaction with dendritic cells 65 
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rather than immunosuppression may reinforce tissue immunity, improve barrier function 66 
and prevent B-cell dysfunction in microbiota-associated disease and IBD etiology. 67 
 68 
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Introduction 75 
Large numbers of lymphocytes reside in the intestinal mucosa and play a key role in barrier 76 
function and immune surveillance. Immunity against infection is provided by long-lived 77 
memory T-cells reactive to foreign antigens as well as antibody1. Memory T-cells can be 78 
broadly categorized into circulating (central memory and effector memory) and tissue-79 
resident, non-recirculating cells called resident memory T-cells (Trm)2. Trm provide potent 80 
barrier immunity in mucosal tissues due to their high motility, rapid re-activation of effector 81 
function and ability to recruit further immune responses via cytokine (e.g. IFN-γ) secretion. 82 
However, the role of Trm in human disease is unclear, and how they interact with resident 83 
microbes that make up the intestinal microbiota is not understood. 84 
Inflammatory bowel disease (IBD) is thought to be perpetuated by intestinal microbial 85 
dysbiosis leading to episodic colitis (ulcerative colitis, UC) or localized inflammation 86 
anywhere along the gastrointestinal (GI) tract (Crohn’s disease, CD), mediated by Th17 or 87 
other subsets of CD4 T-cells3,4. Disease etiology involves interaction of multiple genetic 88 
susceptibilities with environmental factors including diet and lifestyle factors that can affect 89 
the microbiota. However, most studies to date have focussed on sequence-based profiling 90 
of microbiomes in disease; how different microbial species interact with the immune system 91 
is not well understood. Mouse studies indicate the colonic microbiota is essential for 92 
recruiting sufficient CD4 Foxp3-expressing regulatory T-cells (Treg) to the colon to prevent 93 
inflammation5,6. This suggests that IBD results from a failure of Treg-mediated tolerance to 94 
commensals in the GI tract.  95 
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Here we studied memory T-cell responses to a panel of intestinal commensal bacteria in IBD 96 
patients and healthy controls, and analyzed Trm populations in the epithelium and lamina 97 
propria colonic tissue where they are in close proximity to mucosa-associated microbes. Our 98 
data show that underlying disease in human IBD is related to a lack ofassociated with 99 
reduced CD8 T-cell responses to commensal bacteria leading to Trm deficiency in the colon, 100 
and chronic B-cell activation and excess IgA secretion associated with a loss of barrier 101 
immunity. We also show that human Trm express Treg function and propose specific 102 
mechanisms to explain how loss of Trm:dendritic cell interaction could contribute to the 103 
development of inflammatory disease.  104 
 105 
  106 
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Methods 107 
Study Design 108 
The study aimed to determine the role of resident memory T cells in IBD. Donors (age 16-80) 109 
were recruited to the study from outpatient clinics of St Mark’s Hospital and included those 110 
with a diagnosis of CD or UC, and healthy donors undergoing investigative endoscopy. None 111 
of the CD patients had a history of obstruction, perianal disease or ileitis alone. Patients 112 
were recruited over a fixed period determined by ethical permission, no data were excluded 113 
at the end of the study. Additional healthy blood donors were recruited from hospital staff 114 
and visitors. Ethics approval was obtained from the Health Research Authority UK and 115 
London Brent Research Ethics Committee. Written informed consent was received from 116 
participants prior to inclusion in the study. 117 
Colonic intraepithelial lymphocytes (IEL), lamina propria lymphocytes (LPL) and 118 
intraepithelial microbe (IEM) isolation 119 
5 left colon and 5 right colon biopsies (10mg tissue each) were obtained from uninflamed 120 
tissue at routine colonoscopy as described7. IEL and IEM were released from biopsies using 121 
DTT/EDTA and harvested by centrifugation at 300g (5min). IEM were obtained by 122 
centrifugation of resulting supernatants at 4500g (20min). LPL were obtained by collagenase 123 
digestion of remaining tissue; all cells were phenotyped and counted by flow cytometry. 124 
Cells were washed in PBS and stained for viability using LIVE/DEAD Fixable-near-IR stain 125 
(ThermoFisher) before addition of surface-staining antibodies in fetal calf serum. In some 126 
cases cells were then fixed/permeabilized for intranuclear staining using the Foxp3 buffer 127 
set (ThermoFisher, as instructions). Antibodies used are listed in supplementary file 1. All 128 
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samples were analyzed on a BD Biosciences FACS Canto II and data analyzed by FlowJo 129 
software (Tree Star), with volumetric sampling determined using Perfect-Count 130 
microspheresTM (Cytognos, S.L). 131 
In vitro differentiation of Trm-like cells from human PBMC 132 
Naïve CD8 T-cells were purified by magnetic selection from healthy donor PBMC using the 133 
naïve CD8 T-cell isolation kit (Miltenyi Biotec) and were >98% CD8+ and >98% CD45RA+. 134 
Naïve CD8 T-cells were stimulated with plate-bound anti-CD3 (1µg/ml), soluble anti-CD28 135 
(1µg/ml) and IL-2 (5ng/ml, Peprotech). Further additions of TGF-β (3 ng/ml, R&D Systems), 136 
IFN-β (10 ng/ml, R&D), all-trans retinoic acid (ATRA, 10nM, Sigma), FICZ (AhR agonist, 137 
100nM, Tocris Bioscience) were made at the start of the 7 day culture. Cultured cells were 138 
washed in PBS, stained for viability and surface or intracellular markers as above. Tc1/Trm-139 
like cells were analysed for cytokine production by re-stimulation with PMA 140 
(20ng/ml)+ionomycin (400ng/ml)+monensin (3µM) for 4h before staining using Foxp3 141 
staining buffer set. 142 
Commensal-specific T and B-cell memory proliferative responses 143 
Commensal species were isolated from the cecum of healthy donors with the exception of 144 
Collinsella aerofaciens, which was from feces8,9,10. Strains were grown anaerobically in 145 
Hungate tubes containing Wilkins-Chalgren broth (37°C for 24h). Aliquots (1ml) were 146 
centrifuged (13,000rpm for 10 min), supernatants removed and cell pellets snap-frozen with 147 
dry ice before storage at -80°C. PBMC were obtained over Ficoll gradients and labelled with 148 
CellTrace VioletTM (1µM, Life Technologies) according to manufacturer’s instructions, then 149 
cultured at 4x106/ml in XVIVO15 serum-free medium (Lonza, +50µg/ml gentamycin (Sigma) 150 
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and penicillin/streptomycin (Life Technologies, 1/100)). 2x105 killed bacteria from 19 species 151 
(as in Fig 5) were added to 0.2ml cultures and microbe-specific CD4+/CD8+ T-cell and B-cell 152 
responses were determined after 7 days culture. Cultured cells were analyzed by staining 153 
with LIVE/DEAD stain, CD4/CD8/CD19/integrin-β7/CLA/CD39. 154 
Suppression assays 155 
A fraction of healthy donor PBMC were cryopreserved before isolation of naïve CD8 T-cells 156 
and differentiation into Tc1- or Trm-like cells as described above. Cells were cultured at 157 
0.5x106/ml in 0.4ml cultures; Tc1 cells were generated with anti-CD3/28+IL-2 only and Trm-158 
like cells with addition of TGF-β, IFN-β, ATRA and FICZ. After 7 days cells were washed and 159 
autologous PBMC thawed before labelling with CellTrace VioletTM. Labelled target cells were 160 
cultured in U-bottom wells (0.2ml XVIVO-15) at 106/ml with or without addition of 161 
unlabelled Tc1/Trm cells and CD39 inhibitor ARL67156 (200µM, Tocris Bioscience). Cells 162 
were stimulated by addition of SEB (0.1µg/ml, Sigma) and stained after 4 days with 163 
LIVE/DEAD stain, CD3/CD4/CD8/ CD25. Cells were gated for CellTrace Violet+ CD8+ T-cells 164 
and fractions of cells which had divided and upregulated CD25 assessed. 165 
Induction of transcription factors and cytokines in DC 166 
PBMC from healthy donors were cultured at 106/ml in RPMI-1640 medium (Sigma) 167 
supplemented with 10% newborn calf serum (Sigma) and antibiotics as above. LPS (1µg/ml), 168 
SEB (10ng/ml, both Sigma), anti-IFN-γ (50µg/ml) or isotype control IgG1 were added. After 169 
overnight culture all cells were stimulated with LPS+poly I:C (1µg/ml, Sigma) + monensin 170 
(3µM) for a further 4h and stained for lineage markers, HLA-DR/CD123/CD11c/T-bet/TNF-α 171 
/IFN-α and LIVE/DEAD stain using Foxp3 buffer set. Gating for singlet mDC and pDC was 172 
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performed as shown in supplementary file 1. Strict gating for CD11c-negative cells was used 173 
to exclude mDC precursors from the pDC gate – this was confirmed by lack of staining for 174 
CD33, CX3CR1 and Axl. 175 
Measurement of antibody responses 176 
IEM were labelled with SYBR Green DNA stain (Life Technologies, 1/100,000), anti-IgA-177 
APC/anti-IgG-APC/Cy7 and analyzed by flow cytometry to determine proportion (%) of 178 
bacteria coated with antibodies in the gut. Circulating antibodies to commensal species 179 
were determined by incubation of plasma (1/10 in 0.1% BSA, 0.5ml) with 1x105 bacteria 180 
(30min), followed by centrifugation (12,000g, 10 min) and staining as for IEM (or isotype 181 
controls for each sample). Intact microbes were gated according to SYBR Green, and ratio of 182 
geometric mean fluorescence intensity of staining for test sample vs isotype control was 183 
used as measure of antibody titre. Plasma IgG antibodies to viruses were measured using 184 
ELISA kits from Abcam according to instructions. 185 
Statistical analysis 186 
GraphPad Prism 7 software (GraphPad, San Diego, CA) was used to plot and analyze the 187 
data. Clinical data were analyzed by two-tailed unpaired t testsone-way ANOVA or where 188 
populations were skewed, two-tailed Mann-WhitneyKruskal-Wallis tests. For in vitro 189 
experiments, data were analyzed using two-tailed paired t tests or one-way ANOVA for 190 
multiple experimental conditions. P values less than 0.05 were considered significant and 191 
indicated by: *:p<0.05; **:p<0.01; ***:p<0.001. 192 
  193 
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Results 194 
Human colonic Trm are identified by CD103 and Runx3 and express Treg markers CD39 and 195 
CD73 196 
To evaluate the role of Trm in IBD, we first identified Trm in intraepithelial lymphocytes (IEL) 197 
and lamina propria lymphocytes (LPL) from healthy control (HC), CD and UC colonic biopsies 198 
(non-inflamed tissue; clinical and demographic patient characteristics are shown in Table 1). 199 
In healthy IEL (Fig 1a) all T-cells including CD8+ or γδ T-cells, expressed the CD69 putative 200 
Trm marker.  However, CD103 distinguished Trm from effector memory T-cells, which was 201 
confirmed by their intranuclear expression of the Runx3 transcription factor, which controls 202 
the Trm transcriptional program in mice11. A fraction of Trm expressed T-bet, which controls 203 
the Th1 program of differentiation12. In LPL (Fig 1b), main populations were CD4+ and CD8+ 204 
T-cells and the latter not only contained a much larger proportion of CD103+ Trm-like cells 205 
but also had higher levels of Runx3 and T-bet than their CD4 counterparts. IEL lacked CD4 206 
cells and no γδ T-cells were found in LPL.  Trm and γδ T-cells expressed high levels of the 207 
Treg markers CD39 and CD73, suggesting immunosuppressive function (Figs 1c/1d). CD8 208 
Trm were nearly all conventional T-cells expressing CD8αβ heterodimer (Fig 1c) and no 209 
Foxp3 transcription factor (Fig 1d). The vast majority of cells expressing CD39 and CD73 210 
were also Foxp3- (barring a small fraction of the CD4 Trm) suggesting that the Trm 211 
themselves contribute to maintaining tissue homeostasis. 212 
Trm are deficient in Crohn’s disease and ulcerative colitis 213 
Using this analysis we next compared numbers and phenotype of CD8+ and CD4+ Trm and γδ 214 
T-cells obtained from right colon of HC, CD and UC donors (Fig 2).  We found a dramatic 215 
decrease in both CD8 Trm and γδ T-cells in IEL in IBD patients (Fig 2a; 84% and 61% for CD8 216 
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Trm; 90% and 87% for γδ T-cells in CD and UC, respectively). Both total numbers and 217 
percentages of Trm relative to total live cells were reduced in IBD donors. The phenotype of 218 
CD8 Trm was unchanged, but significantly decreased γδ T-cell expression of CD39 and CD73 219 
was seen in UC and CD, respectively, suggesting impaired regulatory function. In LPL, there 220 
were also fewer Trm, although the deficiency was less dramatic than in IEL (61% and 44% for 221 
CD8; 28% and 68% for CD4 in CD and UC respectively) and did not reach statistical 222 
significance for CD4 Trm in CD or when expressed in percentage terms (Fig 2b). There was 223 
no change in phenotype of LPL Trm in disease. Total yields of viable cells in IEL and LPL were 224 
unchanged in IBD (Fig 2c); thus deficiencies in Trm were selective and could not be 225 
explained by loss of epithelium. We also found a strong correlation between numbers of 226 
CD8 Trm in IEL and γδ T-cells (Fig 2d), suggesting co-dependence of these populations. In left 227 
colon biopsies we found significantly fewer Trm (supplementary file 2, Fig S1) and no 228 
significant changes in IBD. 229 
Human Trm development in vitro is controlled by TGF-β, IFN-β, retinoic acid and AhR 230 
receptor agonists 231 
To determine possible mechanisms contributing to the deficiency of Trm in IBD we studied 232 
micro-environmental factors. We developed an in vitro model to induce human Trm-like 233 
cells from naïve CD8 T-cells purified from healthy donor PBMC (Fig 3). Seven days 234 
differentiation with anti-CD3/CD28 and IL-2 yielded effector cells with few markers of Trm 235 
with the exception of the CD73 Treg-associated molecule, and were designated Tc1 type. 236 
We tested addition of TGF-β, a mucosal cytokine known to promote mouse Trm 237 
development2; IFN-β, since type 1 interferon in the gut can control colitis13; all-trans retinoic 238 
acid (ATRA), known to induce CD10314; and FICZ (5,11-Dihydroindolo[3,2-b]carbazole-6-239 
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carboxaldehyde), an aryl hydrocarbon receptor (AhR) agonist known to promote 240 
development of IEL15. Different Trm markers were induced differentially by each factor or 241 
combinations thereof. CD103 expression was dependent on TGF-β alone; CD39 was induced 242 
by IFN-β and FICZ, as was the Trm transcription factor Runx3. Integrin-β7, not a Trm marker 243 
but indicative of gut-homing potential, was induced by a combination of TGF-β and ATRA, as 244 
was CD69, a Trm marker expressed on all intestinal T-cells. Cells expressing all Trm-245 
associated markers simultaneously (Fig 3b) were maximal using A a combination of all four 246 
factors, which were was therefore used to induce Trm-like cells in further functional 247 
experiments. IL-15, although involved in mouse Trm development, had no effect in this 248 
model. 249 
B-cells are dysregulated in quiescent IBD patients 250 
To determine if reduced CD8 T-cells in colonic tissue of IBD patients was 251 
indicative of imbalance in cell-mediated immunity versus humoral immunity towards the 252 
microbiota, we examined proportions of follicular helper (Tfh-like) cells, key inducers of 253 
antibody production through interaction with B-cells in germinal centres, alongside the gut-254 
homing function of T-cells in PBMC (Fig 4a and Fig S3). Tfh-like cells expressing CD4 and 255 
CXCR5 were unchanged in IBD, as were proportions of integrin-β7+, gut-homing cells. CD8 T-256 
cells did not express CXCR5 but showed high levels of integrin-β7 indicating their gut-257 
homing capacity was not impaired in IBD. Analysis of B-cell subsets in PBMC (Fig 4b, Table 2) 258 
showed significantly increased proportions of plasmablasts (CD38hi CD27+ B-cells) in both CD 259 
and UC; these are a highly activated subset destined to become plasma cells in tissues16. 260 
Other B-cell subsets, including those switched to IgA or IgG production were unchanged. 261 
Consistent with increased B-cell activity, IEM released from colonic biopsies showed 262 
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significantly higher levels of IgA coating in both CD and UC than in HC (Figs 4c/4d), although 263 
numbers of microbes obtained was unchanged. 264 
T- and B-cell memory responses to commensal bacteria indicate skewing to humoral 265 
immunity in IBD 266 
We then analyzed whether antigen-specific T- and B-cell responses to specific commensal 267 
bacteria were imbalanced in IBD (Fig 5). We selected 19 commensal strains mainly isolated 268 
from healthy human cecum, covering as many genera as possible. Killed bacteria were 269 
added to PBMC for 7 days to identify specific memory CD4/CD8 T-cell or B-cell proliferative 270 
responses. Results showed responses were highly specific to individual species (Fig 5a/5b) 271 
and showed high degrees of variability both between individual donors and between HC and 272 
IBD patients (Fig 5c). Variability within responses of individual donors was noted after 273 
around one year (Fig S2), indicating such memory is dynamic and not long-term. As 274 
expected CD4 T-cell responses were the predominant memory response in all groups; 275 
however, total numbers of positive responses for each donor were unchanged in health vs 276 
IBD (Fig 5d). By contrast, numbers of the less frequent CD8 T-cell responses were 277 
significantly reduced in CD compared with HC, with the same trend apparent in UC (Fig 5d). 278 
B-cell memory responses to bacteria were rare in health but significantly increased in both 279 
CD and UC (Fig 5d). T-cells proliferating in response to microbes expressed integrin-β7 (gut-280 
homing marker), CLA (skin-homing) and the CD39 Treg marker, while B-cells only expressed 281 
CLA in response to microbes (Fig 5a/Fig S3). 282 
To investigate a possible link between circulating CD8 memory to commensals and 283 
recruitment of CD8 Trm to mucosa, we correlated numbers of CD8 responses to the 19 284 
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bacteria with CD8 Trm (IEL) numbers in donors where both blood and biopsies were 285 
obtained; this indicated a significant positive correlation (Fig 5e). We then examined the 286 
magnitude of individual responses, as reflected by the proportion of divided cells, which is 287 
related to antigen-specific precursor frequency. Results for the most immunogenic species 288 
from each phylum (Fig 5f) show the high level of variability between donors, with significant 289 
differences in CD8 response in health vs IBD revealed for Staphylococcus epidermidis and 290 
Escherichia coli only, the two most immunogenic species. B-cell responses however were 291 
significantly increased for all species in CD and UC. We also categorized numbers of 292 
proliferative responses against the four phyla of bacterial species (Fig S4). The same trends 293 
were observed in all phyla, with the most significant differences in CD8 and B-cell responses 294 
seen in Actinobacteria and Firmicutes. We also performed assays for commensal-specific 295 
antibodies in plasma, a more conventional readout for B-cell immunity. Circulating IgG 296 
specific for the most immunogenic species in the 19-strain panel, as shown in Fig 6a, 297 
showed that antibody was increased in CD but not UC- indeed levels in UC were the same as 298 
those in HC and significantly lower than in CD. Antibodies to less immunogenic species were 299 
detectable but not significantly different between health and IBD. The divergent findings 300 
with B-cell proliferative response vs circulating IgG were reflected in poor correlations 301 
between the levels of each in individual donors; the only statistically significant correlation 302 
was found with E. coli (Fig 6b). Circulating IgA levels were much lower than IgG (Fig S5) or 303 
undetectable, and did not show significant differences between health and disease.  304 
We tested whether immune deviation seen in IBD was specific to microbiota or reflected a 305 
systemic bias affecting responses to other antigens. We chose to assess responses to classic 306 
CD8 T-cell-inducing viral antigens. Plasma were assayed for IgG to three non-enteric viruses 307 
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encountered in childhood – varicella-zoster (VZV), measles and respiratory syncytial virus 308 
(RSV) (Fig 6c). Antibody to VZV showed the same pattern as commensals, with significantly 309 
increased levels in CD but not UC. Antibodies to measles were detectable in all patient 310 
groups but did not differ significantly, while few positive titres of RSV IgG were detected. 311 
Mechanisms of immune deviation in IBD 312 
The above data clearly indicated a pattern of immune deviation between cellular/cytotoxic 313 
and humoral immunity to members of the intestinal microbiota as an underlying feature of 314 
IBD. To examine potential pathogenic mechanisms, we first pursued the hypothesis that 315 
Trm express regulatory T-cell function. We performed suppression assays using 316 
conventional Tc1-type CD8 effector cells and Trm-like cells, generated using our in vitro 317 
model system (Fig 3). The targets used in the assays were autologous PBMC stored in liquid 318 
nitrogen. Effector cells were added at a 1:4 ratio and an inhibitor of CD39 ectonucleotidase 319 
activity (ARL67156) used to determine whether suppressive activity was CD39-dependent. 320 
Target CD8 T-cell proliferation assayed after 4 days revealed suppressive activity in Trm but 321 
not Tc1 cells, which was partially reversed in the presence of the CD39 inhibitor (Fig 7a). The 322 
cultured Tc1 and Trm cells were also tested for cytokine production (Fig 7b), which revealed 323 
that Trm cells had similar capacity for production of pro-inflammatory cytokines IFN-γ, TNF-324 
α and IL-17 compared to Tc1; however IL-10, the key immunoregulatory cytokine in the GI-325 
tract17, was significantly increased in Trm cells. Since dendritic cells (DCs) are critical for 326 
controlling immune deviation and tolerogenic responses and are a target of Treg, we 327 
analyzed the interaction between T-cells and DCs, again using a model system with healthy 328 
PBMC. To stimulate DC: T-cell cognate interactions we used SEB superantigen, compared to 329 
TLR-mediated DC stimulation using LPS (Fig 7c). We also added LPS + poly I:C + monensin to 330 
17 
 
 
cultures for the final 4h in order to assess DC cytokine production. SEB but not LPS strongly 331 
induced T-bet transcription factor expression in both myeloid (mDC) and plasmacytoid DC 332 
(pDC), and those DC expressing T-bet produced less TNF-α and more IFN-α, cytokines with 333 
opposing roles in colitis13,18-20. In pDC, overall TNF-α production was suppressed by SEB, 334 
whilst in mDC the reduced levels in T-bet+ DC were counterbalanced by increased TNF-α in 335 
T-bet- cells. The effect of T-cell:DC interaction on T-bet was partially dependent on IFN-γ, as 336 
shown by a neutralizing IFN-γ antibody, but effects on cytokine production appeared IFN-γ-337 
independent. 338 
 339 
  340 
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Discussion 341 
IBD is characterized by acute inflammatory episodes and pathology, and current treatments 342 
aim to suppress symptoms using a plethora of immunosuppressive strategies. Our studies 343 
here, focussing mainly on patients with little or no active inflammation, reveal 344 
that underlying disease is characterized by reduced CD8 T-cell immunity to 345 
commensal microbes associated with a paucity of Trm, potentially explaining the loss of 346 
barrier immunity which characterizes IBD and drives pathology. Reduced CD8 347 
response can also explain the skewing of immunity towards B-cell-mediated antibody 348 
production, and loss of immunoregulation in the local mucosa due to the reduced numbers 349 
of cells expressing key Treg molecules CD39 and CD73. The mutually antagonistic 350 
relationship between cell-mediated and humoral immunity was first noted in the 1970s21 351 
and was subsequently attributed to the Th1/Th2 axis22,23, as was the hygiene hypothesis in 352 
immune-mediated disease24. CD8 T-cell responses skew immunity away from humoral and 353 
towards cellular immunity – our study is the first to examine such responses to the intestinal 354 
microbiota in humans and points towards novel strategies in IBD treatment. Studies of anti-355 
inflammatory commensal-induced pathways in the gut have focussed on CD4 Foxp3 Treg, 356 
which form a small fraction of the LPL and are absent from IEL in human colon. By contrast, 357 
our data show Trm could provide a gatekeeper function, controlling access of mucosal 358 
antigens to germinal centres in lymphoid tissue, and thus Tfh:B-cell interaction, whilst 359 
simultaneously controlling inflammation through breakdown of extracellular ATP25,26. Runx3 360 
has recently been defined as a master transcription factor for development of murine Trm11. 361 
Our data show that human gut Trm preferentially express Runx3, and further co-express 362 
CD39 and CD73, key functional molecules on Treg cells27. CD39 is essential for in vitro 363 
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suppressive activity of Foxp3+ Treg cells due to its ability to degrade extracellular ATP28, 364 
which activates DC29, and CD73 assists further nucleotide breakdown to adenosine, an 365 
immunosuppressive molecule30. ATP is released in mucosal tissue by injury but is also 366 
secreted by bacteria31, explaining the necessity for high expression of these molecules by 367 
Trm, especially IEL, in comparison to circulating T-cells. IEL and in vitro-derived Trm-like cells 368 
expressed lower levels of CD73, suggesting that further breakdown of ADP towards 369 
adenosine occurs further into the mucosa.  370 
Foxp3+ Treg are critical in systemic tolerance and in establishing tolerance to self-antigens in 371 
early life32. Foxp3 was not expressed in CD8 T-cells in the colon, which outnumber CD4 T-372 
cells. Foxp3+ Treg were present at a modest percentage in the CD4 LPL population (around 373 
5%) and were vastly outnumbered by Foxp3-negative CD4 and CD8 T-cells, mostly Trm, 374 
expressing high levels of CD39 and CD73. Arguably the low number of Foxp3+ Treg in human 375 
colon is insufficient to maintain tolerance in the presence of such large antigenic loads from 376 
the microbiota, necessitating accumulation of Trm populations with regulatory capacity. 377 
Since Trm do not differentiate until they reach the tissue33, this would explain why we found 378 
tolerance to commensal bacteria was not systemic, but localized to the gut. Circulating T-379 
cells reactive to commensals would not express regulatory function until resident in the 380 
tissue and would require local tissue factors such as type I IFN and AhR agonists to maintain 381 
their function. This picture contrasts with that emerging from mouse models, most likely 382 
due to far greater antigenic experience and maturity of the adult human immune system 383 
compared to laboratory mice. We found higher proportions of conventional CD8αβ T-cells in 384 
tissue than reported in mice, which may rely more on innate mechanisms and thymus-385 
derived Foxp3+ Treg due to their short lifespan. We also found strong correlation between 386 
20 
 
 
αβ+ and γδ+ T-cells in IEL, implying αβ+ may support γδ+ cell populations in a fashion 387 
analogous to that demonstrated in the thymus34, or co-dependence on tissue-specific 388 
environmental factors. A further correlation was shown between numbers of memory CD8 389 
responses to commensal bacteria and colonic CD8 Trm, suggesting that such responses are 390 
required to recruit and maintain healthy Trm populations. CD8 Trm have recently been 391 
shown to be recruited to skin in response to skin resident microbes in a non-classical MHC-392 
restricted fashion35. This mouse study demonstrated that such Trm exhibited an unusual 393 
phenotype with expression of immunoregulatory genes and wound-healing activity, thus 394 
improving barrier function without inflammation. Our data suggest a similar phenomenon 395 
occurs in the colon but is dependent on classical responses to a wide range of bacterial 396 
antigens. 397 
One recent study demonstrated a pro-inflammatory role for Trm cells in active IBD36, thus 398 
suggesting that Trm can exhibit both pro- and anti-inflammatory activities dependent on the 399 
context. CD4 and CD8 Trm were increased in the lamina propria of inflamed IBD tissue in 400 
this study, and T-cell transfer colitis experiments in mice confirmed that T-cells adopt a Trm 401 
phenotype soon after recruitment to lamina propria in active disease36. The pathologic role 402 
of Trm was dependent on their pro-inflammatory cytokine production regulated by 403 
Hobit/Blimp-1 transcription factors expressed in Trm. However, deletion of Hobit/Blimp-1 in 404 
mouse CD4 T-cells had no effect on their regulatory function or development into Trm36. A 405 
further study compared proportions of CD103+ cells within total gut T cell populations in 406 
inflamed vs uninflamed biopsies from CD and UC patients . This study showed decreased 407 
proportions of CD103+ cells in inflamed tissue; however this could have been due to influx of 408 
effector memory-type cells. Further work in murine systems targeting regulatory function in 409 
Formatted: Superscript
Formatted: Superscript
21 
 
 
Trm and effects on disease susceptibility are therefore warranted. We propose that dual 410 
functionality of Trm cells in homeostatic versus inflammatory conditions would allow 411 
balanced immunity to occur across large areas of tissue exposed to high antigenic loads. 412 
Murine studies have not clearly described the biology of CD4+ Trm and unlike CD8 cells, 413 
Runx3 expression in human CD103+ CD4 cells in LPL was low, so we focussed on CD8+ Trm 414 
activities. Dietary factors retinoic acid and AhR agonists could play a role in expression of 415 
the Trm phenotype within tissue or in Trm survival, in addition to the mucosal cytokine TGF-416 
β and type 1 interferon, both cytokines associated with suppression of colitis13,37-39. Gut type 417 
1 interferon production could be influenced by the enteric virome, which is also altered in 418 
IBD40. ATRA is derived from vitamin A by antigen-presenting cells37 while AhR agonists are 419 
dietary factors contained in cruciferous vegetables and key to gut health15. Combining these 420 
factors in vitro allowed us to develop the first in vitro differentiation model for human Trm, 421 
but also revealed distinct regulation of individual Trm-associated markers. Interestingly 422 
CD39 was co-regulated with Runx3 while CD103 and CD73 were independently regulated. 423 
Circulating IgG antibody to certain commensals was increased in CD but not UC, despite B-424 
cell dysfunction in UC with increased circulating plasmablasts and IgA secretion. Since 425 
inflammatory lesions penetrate deeper into intestinal tissue in CD than UC41, and there is 426 
more involvement of mesenteric lymph nodes in CD than UC42,43, it is possible that longer-427 
lived, higher affinity antibody responses are generated in CD as antigens could access 428 
germinal centres in lymph nodes driving affinity maturation. Circulating B-cell proliferative 429 
responses may reflect shorter term responses with more broadly reactive antibody 430 
synthesis focussed on mucosa. Indeed, repeat assays on individual healthy donors showed 431 
memory responses to commensal bacteria could change within a year, and long-term 432 
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memory is not required for non-pathogenic organisms. The excessive IgA response to 433 
mucosa-associated microbes was apparent in both CD and UC but was not accompanied by 434 
increased circulating Tfh-like cells. Future work could examine microbe-specific Tfh cells but 435 
these might be sequestered in lymphoid tissue. 436 
Mechanisms through which CD8 T-cells might control immune deviation are not entirely 437 
clear, but they are known to regulate CD4 T-cell development. Here CD4 responses were not 438 
altered in IBD, but we did not examine their cytokine profiles, which are skewed towards a 439 
Th17 profile in IBD4. Th17 development is strongly inhibited by IFN-γ44, the major product of 440 
CD8 T-cells. Our data show an additional mechanism could be via induction of T-bet in DCs, 441 
either via interaction with tissue-resident T-cells reactive to microbial antigens, or in 442 
draining lymphoid tissues. T-bet expression in DC is critical in preventing colitis in mice, 443 
since it represses production of TNF-α18,45. Consistent with this concept, we found 444 
interaction with T-cells suppressed TNF-α in pDC whilst enhancing IFN-α production in DC, 445 
although these effects were less specific to T-cells and IFN-γ. This novel pathway may 446 
contribute to immune deviation and allow acquired immune memory to reinforce DC 447 
activity in tissues. Dialogue between Trm and DC in tissue may inform appropriate type of 448 
memory response as well as directing tissue migration of effector cells. Current dogma 449 
states that DC direct T-cell responses after integrating signals from innate immunity and 450 
tissue damage. However, additional dialogue between tissue DC and Trm would allow for 451 
more intelligent decision-making based on host immunological experiences, thus allowing 452 
the gut immune system to learn which bacteria are pathogenic over time. 453 
IBD is a clear example of a “western” disease associated with dysbiosis and disrupted 454 
immunoregulation46. Our data establish IBD as a disease of B-cell dysfunction and point 455 
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towards a lack ofdeficient CD8 T-cell priming to the microbiota as key to its etiology. IBD 456 
often exhibits extra-intestinal manifestations47, and several other diseases are associated 457 
with intestinal dysbiosis. It is therefore possible that lack ofreduced Trm-priming is a general 458 
mechanism underlying the hygiene hypothesis in immune-mediated disease, and 459 
associations of microbiota with tumour development and cancer therapy48,49. Memory CD8 460 
T-cells migrate to multiple tissues and escape homeostatic control mechanisms that limit 461 
their numbers in the circulation50, so numbers of Trm can accumulate throughout life in 462 
response to immunological experiences. Notably, CD8 Trm accumulate throughout 463 
childhood in humans51, when IBD is often first diagnosed. Since CD8 responses are typically 464 
utilized for dealing with highly pathogenic organisms, a lack of exposure to enteric 465 
pathogens in early life could result in weakened tissue immunity and thus an altered 466 
microbiota. Evidence for this in IBD was provided by the increased antibody response to VZV 467 
seen in CD. VZV is latent and requires constant immune surveillance by cytotoxic T-cells; 468 
thus increased antibody may reflect weaker cytotoxic control of virus, although this was not 469 
the case for measles and RSV.  470 
Manipulating immunity to intestinal microbiota through vaccination may address the 471 
underlying disease process, unlike current immunosuppressive strategies. It may prove of 472 
greater therapeutic benefit than changing the microbiota itself in a range of diseases 473 
associated with dysbiosis, since every patient will respond differently to any particular 474 
microbe/cohort due to MHC differences. Mice which lack T-bet expression in their innate 475 
immune system develop altered microbiota which is colitogenic18, indicating dysbiosis is 476 
secondary to immune changes. Vaccination would need specifically to target CD8 T-cell 477 
responses; inducing cytotoxic activity against target microbes may eliminate them from the 478 
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microbiota, thus preventing pathology. The concept that immunization to induce CD8 T-cell 479 
responses can suppress inflammatory pathology may be counterintuitive, but proof of 480 
principle for this was demonstrated in mouse models of airway disease52,53. Such 481 
vaccination could provide long-lasting effects on the highly plastic DCs that direct immune 482 
responses into pathways associated with health or disease. 483 
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Figure Legends 627 
 628 
Figure 1. Human colonic Trm are identified by CD103 and express Runx3, T-bet and 629 
regulatory T-cell markers but not Foxp3. A: CD8 T-cell and γδ T-cell populations were 630 
identified in IEL fractions and stained for CD69/CD103 surface Trm markers; gated CD103+ 631 
cells were stained for intranuclear Runx3 and T-bet. B: CD4 and CD8 T-cell populations were 632 
identified in LPL fractions and stained for CD69/CD103; gated CD103+ cells were stained for 633 
Runx3 and T-bet. C: IEL CD8+ and γδ T-cell populations were stained for CD39/CD73 Treg-634 
associated ectonucleotidases and CD8αβ to distinguish conventional vs innate-type 635 
lymphocytes. CD8αβ and CD8αα subsets were separately gated and T-bet and Runx3 636 
expression shown, including isotype control staining for transcription factors. D: LPL CD4+ 637 
and CD8+ Trm-like populations were stained for surface CD39/CD73 and intranuclear Foxp3. 638 
Right panels show isotype control for Foxp3 stain. Staining is from right colon biopsies of 639 
healthy donors and is representative of at least 5 individual donors. Similar data were 640 
obtained in left colon.   641 
Figure 2. Quiescent IBD is associated with reduced numbers of Trm and γδ T-cells in colonic 642 
tissue. A: Numbers and percentages of CD8+ γδ TCR- CD103+ Trm recovered from IEL (upper 643 
graphs) and γδ CD103+ T-cells in IEL (lower graphs), alongside CD39 and CD73 expression on 644 
these populations. B: Numbers and percentages of CD4+ CD103+ Trm (upper graphs) and 645 
CD8+ CD103+ Trm (lower graphs) recovered from LPL, alongside CD39 and CD73 expression. 646 
Full gating strategies are shown in supplementary methods. C: Total live cell numbers in 647 
IEL and LPL fractions (including epithelial cells). D: Correlation of CD8 Trm and γδ 648 
T-cell numbers in IEL populations from right colon biopsies of all donors. HC: healthy 649 
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controls, n=25; CD: Crohn’s disease, n=12; UC: ulcerative colitis, n=20. Median values ± 95% 650 
confidence intervals are shown; statistically significant differences between groups (Mann 651 
WhitneyKruskal-Wallis test) are indicated. Spearman correlation coefficient was calculated 652 
in D. 653 
Figure 3. Human CD8 Trm development in vitro is regulated by cytokines, vitamins and 654 
dietary factors. A: Effects of combinations of TGF-β, IFN-β, all-trans retinoic acid (ATRA) and 655 
an AhR agonist (FICZ) on Trm, Treg and homing markers in CD8 effector cells derived from 656 
CD8 naïve T-cells differentiated with anti-CD3/CD28+IL-2 for 7 days. Graphs show mean ± 657 
SEM from 5 independent experiments; groups compared using 1-way ANOVA with Dunn’s 658 
test for multiple comparisons applied. B: Cells expressing all Trm-associated markers 659 
simultaneously were analyzed as in A. C: Staining profiles as in A, showing example of cells 660 
cultured in anti-CD3/28 + IL-2 only (Tc1 cells) or with addition of TGF-β, IFN-β, ATRA and 661 
FICZ (Trm-like cells). 662 
Figure 4. Immunopathology of quiescent IBD reflects B-cell dysregulation. A: Proportions of 663 
Tfh-like (CXCR5+) CD4/CD8 T-cells and gut homing (integrin-β7+) T-cells in PBMC of healthy 664 
control and IBD donors. B: Circulating plasmablasts (CD38hi CD27+ CD19+) and B-cell subsets 665 
in healthy and IBD donors. Mann-WhitneyKruskal-Wallis tests were used to compare groups 666 
(n=23 HC; n=18 CD; n=17 UC). C: IgA coating of IEM obtained from right colon biopsies of 667 
example HC, CD and UC donors, after gating on SYBR Green+ events. D: Pooled data showing 668 
proportions of IgA+ IEM in donor groups. Unpaired t-tests were1-way ANOVA was used to 669 
compare groups (n=25 HC; n=9 CD; n=19 UC). 670 
Figure 5. T- and B-cell memory responses to commensal bacteria show skewing from cell-671 
mediated to humoral immunity in IBD. A: CD4 and CD8 T-cell memory responses to selected 672 
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commensals in healthy PBMC, showing examples of CellTrace Violet dilution in CD4/CD8-673 
gated populations in cultures showing positive and negative responses alongside SEB 674 
positive control; integrin-β7 staining indicates gut-homing potential of expanded antigen-675 
specific cells. B: CD19+ B-cell responses to selected commensals in example CD and UC 676 
patient PBMC; as in A but gated on CD19+ events. C: Representative proliferation data in 677 
PBMC from a HC, CD and UC donor, showing responses to a panel of 19 bacteria after 7 days 678 
stimulation and gating for CD4+ CD8+ and CD19+ cells. D: Pooled data as in C, showing 679 
numbers of positive responses within panel of 19 commensals. Mann-WhitneyKruskal-Wallis 680 
tests were used to compare groups; n=18 HC, n=16 CD&UC. E: Correlation of CD8 681 
proliferative responses in PBMC with CD8 Trm in IEL from autologous biopsies (n=15). Upper 682 
panel shows pooled data with lower panels showing individual correlations for HC and IBD 683 
samples. F: Magnitude of proliferative responses to 4 individual species, one from each 684 
phylum. Pearson correlation coefficient was calculated in E. 685 
Figure 6. Circulating specific IgG antibodies to immunogenic commensal species are raised in 686 
CD but not UC donors. A: Plasma was assayed for IgG antibodies using a coating assay. 687 
Ratios of median fluorescence intensity of anti-IgG-stained vs isotype control for each 688 
sample are shown (median and 95% CIs). Mann-WhitneyKruskal-Wallis tests were used to 689 
compare groups; n=30 HC, n=18 CD&UC. B: Correlation of B-cell proliferative responses to E. 690 
coli against circulating IgG in 40 matched donors, including Pearson correlation coefficient. 691 
Correlations with other species were not significant. C: Antibodies against non-enteric 692 
viruses in health vs IBD. Plasma were assayed by ELISA for IgG to viral antigens and results 693 
expressed in arbitrary units. Grey lines represent cut-off points below which titres are 694 
considered negative. Unpaired t-tests were1-way ANOVA was used to compare groups. 695 
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Figure 7. Mechanisms of immune deviation in IBD. A: Trm-like cells have Treg function 696 
partially dependent on CD39 nucleotidase activity - Tc1 or Trm-like cells were added to 697 
autologous fluorescent labelled PBMC and suppression of CD8 target cell activation was 698 
determined in the presence or absence of the CD39 inhibitor ARL67156. Example staining 699 
and pooled data showing % suppression of proliferation from 3 independent experiments - 700 
mean±SEM, paired t-tests used to compare groups. B: Trm-like cells have increased capacity 701 
for IL-10 secretion. Tc1 and Trm-like cells were restimulated with PMA/ionomycin/monensin 702 
and stained for intracellular cytokines. Example staining and pooled data showing % staining 703 
from 4 independent experiments - mean±SEM, paired t-tests used. C: Induction of T-bet 704 
expression in DC by cognate interaction with T-cells mediated by superantigen is associated 705 
with altered cytokine synthesis - PBMC were cultured overnight with LPS or SEB plus control 706 
antibody/anti-IFN-γ, followed by 4h with LPS+poly I:C+monensin. mDC/pDC populations 707 
were gated according to CD11c/CD123 expression after gating on singlet, viable DC using 708 
lineage vs HLA-DR plots. Example staining and pooled data from 4-5 independent 709 
experiments is shown; paired t-tests were used to compare groups. 710 
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Table 1. Clinical characteristics of St Mark’s Hospital colonoscopy patients 
donating colonic biopsies  
Characteristic HC CD UC 
    
n 23 11 18 
Male/female 13/10 4/7 12/6 
Median age (95% CI) at sampling 51.5 (41-57) 43 (28-57) 53.5 (47-60) 
Median age (95% CI) at diagnosis    26 (18-47) 35 (29-42) 
    
Inflammation scores CD:    
Normal  5  
Erythema  1  
Active ulceration  4  
Severe ulceration/chronic inflammatory change  1  
Ileocolonic disease  3  
    
Inflammation scores UC:    
Mayo 0   8 
Mayo 1   3 
Mayo 2   6 
Mayo 3   1 
    
IBD Medications at sampling:    
Aminosalicylates  4 15 
Azathioprine/6-mercaptopurine  4 1 
Buscopan  1 0 
Adalimumab  1 0 
None  4 3 
    
Non-IBD medications at sampling:    
Metformin/gliclazide/statin  0 2 
Ondansetron  1 0 
Certirazine  1 0 
None  9 16 
    
    
Demographic and clinical data analyzed in Figs 2, 4d, S1 
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 Table 2. Clinical characteristics of St Mark’s Hospital blood donors and 
healthy volunteers  
Characteristic HC CD UC 
    
n 18 17 14 
Male/female 13/5 8/9 7/7 
Median age (95% CI) at sampling 41.5 (30-54) 43.5 (33-61) 54.5 (35-63) 
Median age (95% CI) at diagnosis    25 (20-44) 38.5 (25-47) 
    
Symptoms at sampling:    
Diarrhoea/loose stools  1 2 
Occasional loose motion/watery stool  2 1 
Abdominal pain  2 1 
Peri-anal pain/itch/disease  2 1 
Lethargy  2 0 
Proctitis  0 1 
None  9 8 
    
IBD Medications at sampling:    
Aminosalicylates  8 8 
Azathioprine/6-mercaptopurine  8 2 
Corticosteroids  1 0 
Vedolizumab  1 0 
Antibiotics  1 0 
Methotrexate  1 0 
None  1 6 
    
Non-IBD medications at sampling:    
Vitamins D/D3/B12/multi  4 3 
Metformin/gliclazide  0 2 
Statins  1 2 
Hydroxychloroquine  0 1 
Proton pump inhibitor  0 1 
Alendronate  1 0 
Finasteride  1 0 
Loperamide  1 1 
None  12 9 
    
    
Demographic and clinical data analyzed in Figs 4, 5, 6, S3, S4 
 
 
 
 
